Evidence map›Paper›PMID 32817311›Full record

Trial reportJournal of the American Society of Nephrology : JASN2020

Vitamin K Supplementation to Improve Vascular Stiffness in CKD: The K4Kidneys Randomized Controlled Trial.

Miles D Witham, Jennifer S Lees, Myra White, Margaret Band, Samira Bell, Donna J Chantler, Ian Ford, Roberta L Fulton, Gwen Kennedy, Roberta C Littleford and 11 more

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of the American Society of Nephrology : JASN, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 4 pooled it
6.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 64 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Inhibit progression of coronary artery calcification with vitamin K in hemodialysis patients (the iPACK-HD study): a randomized, placebo-controlled multi-center, pilot trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Trial
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 5 institutions in 2 countries.

Miles D WithamAGE Research Group, National Institute for Health Research Newcastle Biomedical Research Centre, Translational and Clinical Research Institute, Newcastle University and Newcastle-upon-Tyne National Health Service Trust, Tyne, United Kingdom Miles.Witham@newcastle.ac.uk.
Jennifer S LeesInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Myra WhiteSchool of Medicine, University of Dundee, Dundee, United Kingdom.
Margaret BandTayside Clinical Trials Unit, Ninewells Hospital, Dundee, United Kingdom.
Samira BellSchool of Medicine, University of Dundee, Dundee, United Kingdom.ORCID 0000-0001-9100-1575
Donna J ChantlerDepartment of Clinical Biochemistry, National Health Service Greater Glasgow and Clyde, Glasgow Royal Infirmary, Glasgow, United Kingdom.
Ian FordRobertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0001-5927-1823
Roberta L FultonSchool of Nursing and Health Sciences, University of Dundee, Dundee, United Kingdom.
Gwen KennedySchool of Medicine, University of Dundee, Dundee, United Kingdom.
Roberta C LittlefordUniversity of Queensland, Brisbane, Queensland, Australia.
Ian V McCreaDepartment of Radiology, National Health Service Greater Glasgow and Clyde, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
Deborah McGlynnClinical Research Facility, National Health Service Greater Glasgow and Clyde, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
Maurizio PanarelliDepartment of Clinical Biochemistry, National Health Service Greater Glasgow and Clyde, Glasgow Royal Infirmary, Glasgow, United Kingdom.
Maximilian R RalstonInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Elaine RutherfordInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.
Alison SevernRenal Unit, National Health Service Tayside, Ninewells Hospital, Dundee, United Kingdom.
Nicola ThomsonClinical Research Facility, National Health Service Greater Glasgow and Clyde, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
Jamie P TraynorClinical Research Facility, National Health Service Greater Glasgow and Clyde, Queen Elizabeth University Hospital, Glasgow, United Kingdom.ORCID 0000-0002-4339-0366
Allan D StruthersSchool of Medicine, University of Dundee, Dundee, United Kingdom.
Kirsty WetherallRobertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom.
Patrick B MarkInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom.ORCID 0000-0003-3387-2123
National Health Service · GBUniversity of Glasgow · GBUniversity of Dundee · GBNinewells Hospital · GBThe University of Queensland · AU

Funding

British Heart Foundation PG/14/75/31083Chief Scientist Office PCL/20/10Department of Health
6 · The paper itself

Abstract

backgroundVascular calcification, a risk factor for cardiovascular disease, is common among patients with CKD and is an independent contributor to increased vascular stiffness and vascular risk in this patient group. Vitamin K is a cofactor for proteins involved in prevention of vascular calcification. Whether or not vitamin K supplementation could improve arterial stiffness in patients with CKD is unknown.

methodsTo determine if vitamin K supplementation might improve arterial stiffness in patients in CKD, we conducted a parallel-group, double-blind, randomized trial in participants aged 18 or older with CKD stage 3b or 4 (eGFR 15-45 ml/min per 1.73 m

resultsWe included 159 randomized participants in the modified intention-to-treat analysis, with 80 allocated to receive vitamin K and 79 to receive placebo. Mean age was 66 years, 62 (39%) were female, and 87 (55%) had CKD stage 4. We found no differences in pulse wave velocity at 12 months, augmentation index at 12 months, BP, B-type natriuretic peptide, or physical function. The updated meta-analysis showed no effect of vitamin K supplementation on vascular stiffness or vascular calcification measures.

conclusionsVitamin K2 supplementation did not improve vascular stiffness or other measures of vascular health in this trial involving individuals with CKD. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Vitamin K therapy to improve vascular health in patients with chronic kidney disease, ISRCTN21444964 (www.isrctn.com).

Indexed as

Dietary SupplementsAgedDouble-Blind MethodDrug Administration ScheduleFemaleHumansMaleMiddle AgedPulse Wave AnalysisRenal Insufficiency, ChronicTreatment OutcomeVascular CalcificationVascular StiffnessVitamin K 2VitaminsVitamin K 2Vitaminsarterial stiffnesschronic kidney diseasevascular calcificationvitamin K

Identifiers

PMID32817311
PMCPMC7609010
OpenAlexW3080086705

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.